Daito Pharmaceutical Co.,Ltd. (4577.T)
JPY 2025.0
(0.75%)
JPY 2025.0
(0.75%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 3.29 Billion JPY | -8.47% |
| 2022 | 3.6 Billion JPY | -22.88% |
| 2021 | 4.66 Billion JPY | 9.94% |
| 2020 | 4.24 Billion JPY | 7.64% |
| 2019 | 3.94 Billion JPY | 12.29% |
| 2018 | 3.51 Billion JPY | 15.49% |
| 2017 | 3.04 Billion JPY | 14.52% |
| 2016 | 2.65 Billion JPY | 3.5% |
| 2015 | 2.56 Billion JPY | 14.26% |
| 2014 | 2.24 Billion JPY | 24.0% |
| 2013 | 1.81 Billion JPY | 1.39% |
| 2012 | 1.78 Billion JPY | 28.61% |
| 2011 | 1.38 Billion JPY | 40.23% |
| 2010 | 990.61 Million JPY | 31.66% |
| 2009 | 752.38 Million JPY | 8.57% |
| 2008 | 692.96 Million JPY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 617 Million JPY | -35.46% |
| 2023 Q3 | 787 Million JPY | -9.44% |
| 2023 Q4 | 956 Million JPY | 21.47% |
| 2023 FY | 3.29 Billion JPY | -8.47% |
| 2023 Q2 | 869 Million JPY | 27.23% |
| 2023 Q1 | 683 Million JPY | -27.34% |
| 2022 Q3 | 898 Million JPY | 10.05% |
| 2022 Q1 | 946 Million JPY | 37.13% |
| 2022 Q2 | 816 Million JPY | -13.74% |
| 2022 FY | 3.6 Billion JPY | -22.88% |
| 2022 Q4 | 940 Million JPY | 4.68% |
| 2021 Q4 | 689.85 Million JPY | -42.56% |
| 2021 Q1 | 1.82 Billion JPY | 233.93% |
| 2021 Q2 | 951.98 Million JPY | -47.84% |
| 2021 FY | 4.66 Billion JPY | 9.94% |
| 2021 Q3 | 1.2 Billion JPY | 26.16% |
| 2020 Q2 | 1.1 Billion JPY | -16.59% |
| 2020 Q3 | 1.27 Billion JPY | 15.79% |
| 2020 Q4 | 546.54 Million JPY | -57.18% |
| 2020 Q1 | 1.32 Billion JPY | 87.81% |
| 2020 FY | 4.24 Billion JPY | 7.64% |
| 2019 Q1 | 920.35 Million JPY | -4.39% |
| 2019 FY | 3.94 Billion JPY | 12.29% |
| 2019 Q2 | 1.08 Billion JPY | 17.62% |
| 2019 Q3 | 1.23 Billion JPY | 14.39% |
| 2019 Q4 | 703.57 Million JPY | -43.18% |
| 2018 Q3 | 876.83 Million JPY | -1.89% |
| 2018 Q2 | 893.76 Million JPY | 14.61% |
| 2018 Q4 | 962.56 Million JPY | 9.78% |
| 2018 FY | 3.51 Billion JPY | 15.49% |
| 2018 Q1 | 779.86 Million JPY | 5.15% |
| 2017 Q3 | 713.17 Million JPY | -21.95% |
| 2017 Q1 | 673.29 Million JPY | 9.9% |
| 2017 FY | 3.04 Billion JPY | 14.52% |
| 2017 Q4 | 741.69 Million JPY | 4.0% |
| 2017 Q2 | 913.77 Million JPY | 35.72% |
| 2016 Q1 | 671.63 Million JPY | 2.56% |
| 2016 FY | 2.65 Billion JPY | 3.5% |
| 2016 Q4 | 612.62 Million JPY | -1.14% |
| 2016 Q3 | 619.68 Million JPY | -17.63% |
| 2016 Q2 | 752.33 Million JPY | 12.02% |
| 2015 FY | 2.56 Billion JPY | 14.26% |
| 2015 Q1 | 678.7 Million JPY | -6.72% |
| 2015 Q4 | 654.86 Million JPY | 1.74% |
| 2015 Q3 | 643.63 Million JPY | 9.24% |
| 2015 Q2 | 589.2 Million JPY | -13.19% |
| 2014 Q4 | 727.56 Million JPY | 78.22% |
| 2014 Q1 | 456.61 Million JPY | -18.74% |
| 2014 Q2 | 653.7 Million JPY | 43.16% |
| 2014 FY | 2.24 Billion JPY | 24.0% |
| 2014 Q3 | 408.24 Million JPY | -37.55% |
| 2013 Q4 | 561.94 Million JPY | 66.28% |
| 2013 FY | 1.81 Billion JPY | 1.39% |
| 2013 Q3 | 337.96 Million JPY | -33.43% |
| 2013 Q1 | 403.77 Million JPY | -38.91% |
| 2013 Q2 | 507.71 Million JPY | 25.74% |
| 2012 Q3 | 215.63 Million JPY | -58.47% |
| 2012 FY | 1.78 Billion JPY | 28.61% |
| 2012 Q2 | 519.24 Million JPY | 32.85% |
| 2012 Q1 | 390.83 Million JPY | 28.65% |
| 2012 Q4 | 660.92 Million JPY | 206.51% |
| 2011 Q1 | 304.16 Million JPY | 80.86% |
| 2011 FY | 1.38 Billion JPY | 40.23% |
| 2011 Q2 | 566.23 Million JPY | 86.16% |
| 2011 Q3 | 214.93 Million JPY | -62.04% |
| 2011 Q4 | 303.8 Million JPY | 41.34% |
| 2010 Q1 | 164.79 Million JPY | 0.0% |
| 2010 Q3 | 304.09 Million JPY | -13.99% |
| 2010 FY | 990.61 Million JPY | 31.66% |
| 2010 Q4 | 168.17 Million JPY | -44.7% |
| 2010 Q2 | 353.54 Million JPY | 114.53% |
| 2009 Q2 | 265.25 Million JPY | 0.0% |
| 2009 FY | 752.38 Million JPY | 8.57% |
| 2008 FY | 692.96 Million JPY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 3.2 Billion JPY | -2.808% |
| Takeda Pharmaceutical Company Limited | 144.06 Billion JPY | 97.713% |
| Sumitomo Pharma Co., Ltd. | -314.96 Billion JPY | 101.046% |
| Shionogi & Co., Ltd. | 162.03 Billion JPY | 97.966% |
| Wakamoto Pharmaceutical Co.,Ltd. | 108.95 Million JPY | -2924.073% |
| Nippon Shinyaku Co., Ltd. | 25.85 Billion JPY | 87.254% |
| Kaken Pharmaceutical Co., Ltd. | 8.02 Billion JPY | 58.941% |
| Eisai Co., Ltd. | 42.4 Billion JPY | 92.23% |
| Morishita Jintan Co., Ltd. | 697 Million JPY | -372.74% |
| Hisamitsu Pharmaceutical Co., Inc. | 13.96 Billion JPY | 76.412% |
| Mochida Pharmaceutical Co., Ltd. | 4.54 Billion JPY | 27.535% |
| Fuso Pharmaceutical Industries,Ltd. | 1.37 Billion JPY | -139.288% |
| Nippon Chemiphar Co., Ltd. | -180 Million JPY | 1930.556% |
| Tsumura & Co. | 16.7 Billion JPY | 80.278% |
| Kissei Pharmaceutical Co., Ltd. | 11.16 Billion JPY | 70.475% |
| Torii Pharmaceutical Co., Ltd. | 4.11 Billion JPY | 20.005% |
| Towa Pharmaceutical Co., Ltd. | 16.17 Billion JPY | 79.627% |
| Fuji Pharma Co., Ltd. | 3.43 Billion JPY | 4.076% |
| Zeria Pharmaceutical Co., Ltd. | 7.73 Billion JPY | 57.381% |
| KYORIN Holdings, Inc. | 5.32 Billion JPY | 38.087% |
| Taiko Pharmaceutical Co.,Ltd. | -4.89 Billion JPY | 167.327% |
| SymBio Pharmaceuticals Limited | -1.96 Billion JPY | 267.871% |
| MedRx Co., Ltd | -932 Million JPY | 453.541% |
| Mizuho Medy Co.,Ltd. | 3.77 Billion JPY | 12.698% |
| Solasia Pharma K.K. | -1.11 Billion JPY | 396.313% |
| Modalis Therapeutics Corporation | -2.39 Billion JPY | 237.761% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 7.54 Billion JPY | 56.329% |
| Sawai Group Holdings Co., Ltd. | 13.69 Billion JPY | 75.94% |
| Cyfuse Biomedical K.K. | -589.21 Million JPY | 659.222% |
| Toho Holdings Co., Ltd. | 20.65 Billion JPY | 84.049% |
| Koa Shoji Holdings Co.,Ltd. | 2.94 Billion JPY | -11.834% |